ELI LILLY & Co

Company facts

Industry

Pharmaceutical Preparations

Headquarters

Indianapolis, Indiana

Most recent report

10-Q, filed Oct 29, 2026

Incorporated

Indiana

Filings on record

1,001+ filings

On EDGAR

CIK 59478

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 11 sections worth reading, with 2 positive, 8 notable, and 3 negative flags.

• Financial Statements (Item 1)

  Massive acquisition spend, debt jump, and inventory build define this period's financial profile.
  Notable

  • Prepaid taxes of $15.1B at Sep 2026, up from $12.9B at Dec 2025, a large cash outflow.
  • Multiple generic companies filed ANDAs for Mounjaro/Zepbound; patent infringement suits filed in August 2026.
  • Share repurchases were $4.3B in 9M 2026 vs $2.6B in 9M 2025; $6.6B remains under $15B program.
  Negative

  • Federal Circuit reversed invalidity ruling on Emgality patents; charge recognized in Q1 2026.

• Management's Discussion (Item 2)

  Revenue up 46% to $67.2B; Mounjaro/Zepbound/Foundayo = 66% of revenue; $18.2B spent on acquisitions; debt up $7B to $49.5B.
  Positive

  • FDA approved Onswik (insulin efsitora alfa) for type 2 diabetes and Foundayo (orforglipron) for obesity.
  • Retatrutide Phase 3 trials for obesity and type 2 diabetes met primary endpoints.
  Notable

  • Trulicity and Verzenio selected for IRA government price setting (effective 2028); Jardiance already selected.
  • Cash and investments total $9.0B; $862M unfunded venture capital commitments; $10.1B credit facilities.
  • Issued $9.0B in long-term debt in May 2026 to fund acquisitions and repay commercial paper.
  • Paid $4.6B in dividends ($5.19/share) for nine months; Q4 dividend of $1.73/share declared.
  Negative

  • Mounjaro, Zepbound, and Foundayo = 66% of total revenue for nine months; heavy concentration in incretins.
  • Total debt rose $7.0B to $49.5B; $18.2B spent on acquisitions in nine months.

• Unregistered Sales and Repurchases (Item 2)

  Company-specific buyback activity with dollar amounts and remaining authorization.
  Notable

  • Repurchased $374 million in Q3 2026, leaving $6.6B of the $15.0B program unused.

What changed: Sep 2026 vs. Jun 2026

About 7% of LLY's Sep 2026 10-Q is new information. 18 paragraphs were added, 94 changed, and 39 removed. Below are the most important lines SECSift identified.

• Item 2 39
• Item 1 35
• Item 5 5
• Item 4 2
• Item 6 2